Enovis Co. (NYSE:ENOV) Shares Bought by Axa S.A.

Axa S.A. raised its holdings in Enovis Co. (NYSE:ENOV) by 26.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,798 shares of the company’s stock after purchasing an additional 4,326 shares during the quarter. Axa S.A.’s holdings in Enovis were worth $940,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of ENOV. Fidelis Capital Partners LLC acquired a new position in Enovis in the first quarter valued at $34,000. Ridgewood Investments LLC purchased a new stake in shares of Enovis in the second quarter valued at about $44,000. Innealta Capital LLC purchased a new stake in shares of Enovis in the second quarter valued at about $65,000. GAMMA Investing LLC boosted its holdings in shares of Enovis by 19.9% in the first quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock valued at $68,000 after acquiring an additional 180 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after acquiring an additional 371 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 3.7 %

ENOV stock opened at $41.47 on Wednesday. The company has a market cap of $2.27 billion, a P/E ratio of -27.65 and a beta of 1.92. Enovis Co. has a 52 week low of $39.98 and a 52 week high of $65.03. The company’s 50-day moving average price is $44.37 and its 200 day moving average price is $49.10. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. The company had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The firm’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.61 earnings per share. On average, research analysts expect that Enovis Co. will post 2.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday. Needham & Company LLC lowered their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $68.63.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.